Merck Immunotherapy Drug Shines In Lung Cancer Study
Research finds that more than two-thirds of lung cancer patients who received Keytruda plus chemotherapy would be alive a year later, compared with about half of people who only got chemotherapy.
Read more on NPR
No comments:
Post a Comment